Erratum to Eosinophilia in routine blood samples and the subsequent risk of hematological malignancies and death. [Am. J. Hematol. 88, (2013), 843-847] 10.1002/ajh.23515;Eosinophilia in routine blood samples and the subsequent risk of hematological malignancies and death

American Journal of Hematology

Volumn 88, Issue 10, 2013, Pages 843-847

  Andersen, Christen Lykkegaard ^a,b   Siersma, Volkert Dirk ^b   Hasselbalch, Hans Carl ^a   Lindegaard, Hanne ^c   Vestergaard, Hanne ^c   Felding, Peter ^d   de Fine Olivarius, Niels ^b   Bjerrum, Ole Weis ^e  

^a ROSKILDE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d Copenhagen General Practitioners' Laboratory ^*  (Denmark)

^e Copenhagen University Hospital ^*  (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGE; ARTICLE; BLOOD ANALYSIS; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CHARLSON COMORBIDITY INDEX; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; DISEASE ASSOCIATION; DISEASE SEVERITY; EOSINOPHIL COUNT; EOSINOPHILIA; FEMALE; GENDER; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; LEUKOCYTE DIFFERENTIAL COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTIC LEUKEMIA; MULTIPLE MYELOMA; MYELOPROLIFERATIVE NEOPLASM; NEOPLASM; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 84884729584     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23700     Document Type: Erratum

References (29)

1. Blanchard C, Rothenberg ME. Biology of the eosinophil. Adv Immunol 2009;101:81-121.
2. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol 2006;24:147-174.
3. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: Secondary, clonal and idiopathic. Br J Haematol 2006;133:468-492.
4. Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Press: Internationl Agency for Research on Cancer (www.iarc.fr); 2008.
5. Valent P, Gleich GJ, Reiter A, et al. Pathogenesis and classification of eosinophil disorders: A review of recent developments in the field. Expert Rev Hematol 2012;5:157-176.
6. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994;83:2759-2779.
7. Bjerrum OW, Pelliniemi TT, Wadenwik H. Guidelines for the Diagnosis and Treatment of Eosinophilia 2nd version September 2012. Nordic MPN Study Group 2012.
8. Simon D, Simon HU. Eosinophilic disorders. J Allergy Clin Immunol 2007;119:1291-1300; quiz 1301-1292.
9. Vaughan Hudson B, Linch DC, Macintyre EA, et al. Selective peripheral blood eosinophilia associated with survival advantage in Hodgkin's disease (BNLI Report No 31). British National Lymphoma Investigation. J Clin Pathol 1987;40:247-250.
10. Desenne JJ, Acquatella G, Stern R, et al. Blood eosinophilia in Hodgkin's disease. A follow-up of 25 cases in Venezuela. Cancer 1992;69:1248-1253.
11. Roufosse F, Garaud S, de Leval L. Lymphoproliferative disorders associated with hypereosinophilia. Semin Hematol 2012;49:138-148.
12. Gotlib J. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. Am J Hematol 2011;86:677-688.
13. Pearson TC, Messinezy M, Westwood N. A polycythemia vera update: Diagnosis, pathobiology, and treatment. Hematology Am Soc Hematol Educ Program 2000:51-68.
14. Koeffler HP, Levine AM, Sparkes M, et al. Chronic myelocytic leukemia: Eosinophils involved in the malignant clone. Blood 1980;55:1063-1065.
15. Pedersen CB, Gotzsche H, Moller JO, et al. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 2006;53:441-449.
16. Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health 2011;39:42-45.
17. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011;39:30-33.
18. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-383.
19. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Stat Soc B 1995;57:289-300.
20. Endo M, Usuki K, Kitazume K, et al. Hypereosinophilic syndrome in Hodgkin's disease with increased granulocyte-macrophage colony-stimulating factor. Ann Hematol 1995;71:313-314.
21. Samoszuk M, Nansen L. Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood 1990;75:13-16.
22. Pinto A, Aldinucci D, Gloghini A, et al. The role of eosinophils in the pathobiology of Hodgkin's disease. Ann Oncol 1997;8 Suppl 2:89-96.
23. Glimelius I, Rubin J, Fischer M, et al. Effect of eosinophil cationic protein (ECP) on Hodgkin lymphoma cell lines. Exp Hematol 2011;39:850-858.
24. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood 1992;79:3101-3109.
25. Furbert-Harris P, Parish-Gause D, Laniyan I, et al. Inhibition of prostate cancer cell growth by activated eosinophils. Prostate 2003;57:165-175.
26. Sezer O, Schmid P, Hallek M, et al. Eosinophilia during fludarabine treatment of chronic lymphocytic leukemia. Ann Hematol 1999;78:475-477.
27. The Danish Cancer. Available at: Registry http://www.sst.dk/publ/Publ2011/DAF/Cancer/Cancerregisteret2010pdf 2010. Accessed in April, 2011.
28. Haut ER, Pronovost PJ. Surveillance bias in outcomes reporting. JAMA 2011;305:2462-2463.
29. Lichtman MA. Obesity and the risk for a hematological malignancy: Leukemia, lymphoma, or myeloma. Oncologist 2010;15:1083-1101.